Fondazione Luigi Maria Monti

The Fondazione Luigi Maria Monti in Rome is running a broad portfolio in dermatology, with a strong focus on skin and connective tissue diseases such as bullous pemphigoid, epidermolysis bullosa, hidradenitis suppurativa, psoriasis, acne vulgaris, vitiligo, and diabetic foot ulcer. These studies mainly aim to improve symptom control, support wound healing, and assess the safety and effectiveness of new topical or systemic treatments.

• Long-term safety and disease control in bullous pemphigoid and hidradenitis suppurativa
• New treatment options for epidermolysis bullosa and related blistering disorders
• Therapies for psoriasis, acne vulgaris, and vitiligo aimed at improving skin symptoms and quality of life
• Wound-healing approaches for diabetic foot ulcer and other chronic skin conditions

Research at this site is centered on both long-term disease management and the evaluation of innovative skin-directed therapies for patients with chronic and often difficult-to-treat conditions.

Clinical trials in immune system diseases at this site focus on conditions where the immune response plays a major role, including bullous pemphigoid, hidradenitis suppurativa, vitiligo, and psoriasis. The main purpose is to test whether new immune-targeted treatments can better control inflammation, reduce disease activity, and maintain results over time.

• Immune-modulating treatments for bullous pemphigoid and hidradenitis suppurativa
• Studies of vitiligo therapies designed to support repigmentation and disease stabilization
• Evaluation of psoriasis treatments that target immune pathways involved in chronic skin inflammation
• Research on the safety and durability of response for newer immunology-based therapies

These trials reflect a clear interest in refining immune-mediated disease care through treatments that may offer more sustained benefit and improved tolerability.

The neoplasms portfolio at Fondazione Luigi Maria Monti includes studies in melanoma, Merkel cell carcinoma, cervical cancer, ovarian cancer, breast cancer, and other advanced solid tumors. These trials are designed to evaluate new cancer therapies, improve treatment effectiveness, and compare emerging combinations with current standards of care.

• New melanoma treatments for advanced, metastatic, and mutation-specific disease
• Immunotherapy studies in Merkel cell carcinoma and other difficult-to-treat cancers
• Trials in ovarian cancer, cervical cancer, and breast cancer focused on treatment response and disease control
• Research in broader solid tumors exploring whether novel immune-based approaches can improve outcomes

The cancer research program combines immunotherapy, targeted treatment strategies, and comparative effectiveness studies to address both common and rare advanced malignancies.